Prevalence, clinical significance and prognosis value of liver stiffness measurement anomalies in transthyretin cardiac amyloidosis.

Heart failure Liver stiffness measurement Prognosis Transthyretin cardiac amyloidosis

Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
24 Aug 2024
Historique:
received: 14 03 2024
revised: 27 06 2024
accepted: 23 08 2024
medline: 27 8 2024
pubmed: 27 8 2024
entrez: 26 8 2024
Statut: aheadofprint

Résumé

Background - Laboratory liver anomalies are common in cardiac amyloidosis; however, their significance regarding liver stiffness is unknow. The aim of this study was to investigate the prevalence, clinical significance, and prognostic value of liver stiffness measurement (LSM) anomalies in transthyretin cardiac amyloidosis (ATTR-CA). Methods - Consecutive patients diagnosed with ATTR-CA who underwent liver stiffness assessment were included in the study. Demographic, clinical, laboratory, transthoracic echocardiography and liver stiffness data were retrospectively collected. LSM was obtained through either transient elastography or supersonic shear imaging. Patient cohort was divided in two groups according to a 10 kPa threshold. Follow up data were collected for the occurrence of hospitalization for heart failure and all-cause death. Results - Two hundred and eighty-four patients with ATTR-CA - 26 (9 %) hereditary variant ATTR, 258 (91 %) wild-type ATTR - were included. A LSM over 10 kPa was found in 4 (15 %) and 98 (38 %) patients with ATTRv and ATTRwt respectively (p = 0.02). Among patients with ATTRwt, high LSM was more frequent in advanced stages of ATTR-CA and was associated with increased risk of hospitalization for heart failure after multivariate analysis with a hazard ratio of 2.41 [1.05-5.55] (p = 0.04). Among patients with NYHA stage 1, 28 % presented high LSM associated with high NT-proBNP levels. Integration of high LSM with NT-proBNP and estimated glomerular filtration rate provided a better estimate of patient survival. Conclusion - LSM over 10 kPa is found in up to 36 % of patients with ATTR-CA and is associated with advanced stages of CM and increased risk for hospitalization for heart failure in ATTRwt patients.

Identifiants

pubmed: 39187068
pii: S0167-5273(24)01107-0
doi: 10.1016/j.ijcard.2024.132485
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

132485

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest None of the authors has competing interests in this study.

Auteurs

Emmanuelle Lointier (E)

Department of Cardiology, Rangueil University Hospital, Toulouse, France.

Eve Cariou (E)

Department of Cardiology, Rangueil University Hospital, Toulouse, France; Cardiac Imaging Centre, Rangueil University Hospital, France.

Maxime Beneyto (M)

Department of Cardiology, Rangueil University Hospital, Toulouse, France.

Pauline Fournier (P)

Department of Cardiology, Rangueil University Hospital, Toulouse, France; Cardiac Imaging Centre, Rangueil University Hospital, France.

Yoan Lavie-Badie (Y)

Department of Cardiology, Rangueil University Hospital, Toulouse, France; Cardiac Imaging Centre, Rangueil University Hospital, France.

Damien Eyharts (D)

Department of Cardiology, Rangueil University Hospital, Toulouse, France; Cardiac Imaging Centre, Rangueil University Hospital, France.

Christophe Bureau (C)

Hepatology department, Rangueil University Hospital, Toulouse, France; Medical School, Toulouse III Paul Sabatier University, Toulouse, France.

Olivier Lairez (O)

Department of Cardiology, Rangueil University Hospital, Toulouse, France; Cardiac Imaging Centre, Rangueil University Hospital, France; Medical School, Toulouse III Paul Sabatier University, Toulouse, France. Electronic address: lairez.o@chu-toulouse.fr.

Laurent Alric (L)

Department of Internal Medicine and Digestive Diseases, Purpan University Hospital, Toulouse, France.

Christophe Bureau (C)

Department of Hepatology-Gastroenterology, Rangueil University Hospital, Toulouse, France.

Dominique Chauveau (D)

Department of Nephrology and Referral Centre for Rare Diseases, Rangueil University Hospital, Toulouse, France.

Pascal Cintas (P)

Department of Neurology, Purpan University Hospital, Toulouse, France.

Audrey Delas (A)

Department of Pathology, IUCT Oncopôle, Toulouse, France.

Delphine Dupin-Deguine (D)

Department of Genetic, Toulouse University Hospital, Toulouse, France.

Stanislas Faguer (S)

Department of Nephrology and Referral Centre for Rare Diseases, Rangueil University Hospital, Toulouse, France.

Antoine Huart (A)

Department of Nephrology and Referral Centre for Rare Diseases, Rangueil University Hospital, Toulouse, France.

Bénédicte Puissant (B)

Immunology Laboratory, Toulouse University Hospital, Toulouse, France.

Grégory Pugnet (G)

Department of Internal Medicine and Digestive Diseases, Purpan University Hospital, Toulouse, France.

Grégoire Prévot (G)

Department of Pneumology, Toulouse University Hospital, Toulouse, France.

David Ribes (D)

Department of Nephrology and Referral Centre for Rare Diseases, Rangueil University Hospital, Toulouse, France.

Laurent Sailler (L)

Department of Internal Medicine, Toulouse University Hospital, Toulouse, France.

Classifications MeSH